aneurysmal subarachnoid hemorrhage
Conditions
Interventions
experimental group:intravenous sodium valproate
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years old; 2. Modified Rankin Scale (mRS) Score 0-1 before ictus; 3. Computed Tomography Angiography (CTA) or Digital Subtraction Angiography (DSA) confirmed diagnosis of aSAH caused by rupture of anterior circulation aneurysm; 4. Symptoms onset of aSAH occurred < 24 hours prior to presentation at the hospital; 5. Hunt-Hess grade <=3 on admission; 6. Surgical clipping is planned for treatment; 7. Patient is willing and able to accept long-term study follow-up; 8. Patient or their Legally Authorized Representative (LAR) has provided written informed consent.
Exclusion criteria
Exclusion criteria: 1. Concurrent non-ruptured aneurysm on the same admission; 2. SAH secondary to rupture of traumatic or infected aneurysm; 3. Prior anticonvulsant therapy or epilepsy; 4. Seizure before enrollment; 5. Use of carbapenem antibiotics within 7 days before enrollment; 6. History of coagulopathy; 7. Concurrent significant intracranial pathology, including but not limited to Moyamoya disease, arteriovenous malformation, arteriovenous fistula, or malignant brain tumor; 8. Serious co-morbidities, including but not limited to severe major depression, cancer (likely to cause death in 2 years), multi-system organ failure; 9. History of previous ruptured cerebral aneurysm; 10. Liver dysfunction (clinical laboratory markers for liver function 3 times greater than normal or cirrhosis), with acute or chronic hepatitis, history or family history of serious hepatitis (especially drug-induced hepatitis); 11. Known allergy to sodium valproate; 12. Pregnant woman; 13. Patients and/or LAR refuse treatment; 14. Enrollment in another research study that would conflict with this study; 15. Any other reasons that the investigator considers the patient is inappropriate for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| seizure; | — |
Secondary
| Measure | Time frame |
|---|---|
| aSAH-related complications;modified Rankin Score;MoCA Score;all-cause death;good outcome (mRS 0-2); | — |
Countries
China
Contacts
Public ContactHu Xin
Department of Neurosurgery, West China Hospital, Sichuan University
Outcome results
None listed